Skip to main content
. 2022 Feb 7;22:17. doi: 10.1186/s12894-022-00964-2

Table 7.

The comparison of clinicopathological characteristics between p16INK4a/Ki-67/ p53 positive and negative RCC patients (n = 118)

Variable p53 Pos
N (%)
p53
Neg
N (%)
p value P16
Pos
N (%)
P16
Neg
N (%)
p value Ki-67 Pos
N (%)
Ki-67 Neg
N (%)
p value High cyto-
NF-κB
N (%)
Low cyto-
NF-κB
N (%)
p value High nuclear
NF-κB
N (%)
Low nuclear
NF-κB
N (%)
p value
Total 11 (9.3) 107 (90.7) 24 (20.3) 94 (79.7) 24 (20.3) 94 (79.7) 98 (83.0) 20 (16.9) 70 (59.3) 48 (40.7)
Gender
 Male 7 (63.6) 61 (57) 0.757 17 (70.8) 51 (54.3) 0.169 18 (75) 50 (53.2) 0.065 56 (57.1) 12 (60.0) > 0.999 38 (54.3) 30 (62.5) 0.449
 Female 4 (36.4) 46 (43) 7 (29.1) 43 (45.7) 6 (25) 44 (46.8) 42 (42.9) 8 (40.0) 32 (45.7) 18 (37.5)
Age
 ≥ 54 6 (54.5) 57 (53.3) > 0.999 10 (41.6) 53 (56.4) 0.253 15 (62.5) 48 (51.1) 0.364 52 (53.1) 11 (55) > 0.999 42 (60) 21 (43.7) 0.094
 ˂ 54 5 (45.5) 50 (46.7) 14 (58.3) 41 (43.6) 9 (37.5) 46 (48.9) 46 (46.9) 9 (45) 28 (40) 27 (56.2)
Tumor location
 Right 7 (63.6) 58 (54.2) 0.752 14 (58.3) 51 (54.3) 0.819 11 (45.8) 54 (57.4) 0.361 56 (57.1) 9 (45.0) 0.336 36 (51.4) 29 (60.4) 0.353
 Left 4 (36.4) 49 (45.8) 10 (41.6) 43 (45.7) 13 (54.2) 40 (42.6) 42 (42.9) 11 (55.0) 34 (48.6) 19 (39.6)
Tumor grade
 G1 3 (27.2) 50 (46.7) 0.006 9 (37.5) 44 (46.8) 0.280 3 (12.5) 50 (53.2) < 0.0001 36 (36.7) 17 (85.0) 0.003 30 (42.9) 23 (47.9) 0.485
 G2 2 (18.1) 40 (37.3) 8 (33.3) 34 (36.1) 7 (29.2) 35 (37.2) 39 (39.8) 3 (15.0) 23 (32.8) 19 (39.6)
 G3 6 (54.5) 14 (13.1) 7 (29.1) 13 (13.8) 13 (54.2) 7 (7.4) 20 (20.4) 0 15 (21.4) 5 (10.4)
 G4 0 3 (2.8) 0 3 (3.2) 1 (4.1) 2 (2.1) 3 (3.1) 0 2 (2.9) 1 (2.1)
 G1 + G2 5 (45.5) 90 (84.1) 0.007 17 (70.8) 78 (82.9) 0.246 10 (41.7) 85 (90.4) < 0.0001 75 (76.5) 20 (100) 0.012 53 (75.7) 42 (87.5) 0.156
 G3 + G4 6 (54.5) 17 (15.9) 7 (29.1) 16 (17.0) 14 (58.3) 9 (9.6) 23 (23.50 0 17 (24.3) 6 (12.5)
pT category
 pT1 6 (54.5) 49 (45.8) 0.014 11 (45.8) 44 (46.8) 0.209 8 (33.3) 47 (50) 0.0002 42 (42.8) 13 (65) 0.254 31 (44.3) 24 (50) 0.364
 pT2 3 (27.2) 40 (37.3) 6 (25.0) 37 (39.4) 5 (20.8) 38 (40.4) 37 (37.7) 6 (30) 29 (41.4) 14 (29.2)
pT3 1 (9.1) 18 (16.8) 7 (29.1) 12 (12.7) 10 (41.7) 9 (9.6) 18 (18.4) 1 (5) 10 (14.3) 9 (18.7)
 pT4 1 (9.1) 0 0 1 (1.1) 1 (4.2) 0 1 (1.0) 0 0 1 (2.1)
 pT1 + pT2 9 (81.9) 89 (83.2) > 0.999 17 (70.8) 81 (86.1) 0.122 13 (54.2) 85 (90.4) 0.0001 79 (80.6) 19 (95) 0.190 60 (85.7) 38 (79.2) 0.351
 pT3 + pT4 2 (18.1) 18 (16.8) 7 (29.1) 13 (13.8) 11 (45.8) 9 (9.6) 19 (19.4) 1 (5) 10 (14.3) 10 (20.8)
Histologic types
 Conventional 3 (27.3) 70 (65.4) 0.020 a 12 (50) 61 (64.9) 0.239 12 (50) 61 (64.9) 0.239 a 61 (62.2) 12 (60) 0.850 41 (58.6) 32 (66.6) 0.373
 Nonconventional 8 (72.7) 37 (34.6) 12 (50) 33 (35.1) 12 (50) 33 (35.1) 37 (37.7) 8 (40) 29 (41.4) 16 (33.3)
 Papillary 6 (54.5) 20 (18.7) 9 (37.5) 17 (18.1) 8 (33.3) 18 (19.1) 23 (23.4) 3 (15) 20 (28.6) 6 (12.5)
 Chromophobe 1 (9.1) 13 (12.1) 1 (4.1) 13 (13.8) 0 14 (14.9) 9 (9.2) 5 (25) 5 (7.1) 9 (18.7)
 Collecting duct 0 1 (0.9) 0 1 (1.1) 1 (4.2) 0 1 (1.0) 0 1 (1.4) 0
 Unclassified 1 (9.1) 3 (2.8) 2 (8.3) 2 (2.1) 3 (12.5) 1 (1.1) 4 (4.1) 0 3 (4.3) 1 (2.1)
EBV
 Positive 5 (45.4) 28 (26.2) 0.287 8 (33.3) 25 (26.6) 0.611 8 (33.3) 25 (26.6) 0.611 31 (31.6) 2 (10) 0.058 29 (41.4) 4 (8.3) < 0.0001
 Negative 6 (54.5) 79 (73.8) 16 (66.6) 69 (73.4) 16 (66.6) 69 (73.6) 67 (68.4) 18 (90) 41 (58.6) 44 (91.7)

Pos positive, Neg negative, Cyto cytoplasmic, P16 p16INK4a, pT primary tumor